No Non-Inferiority in Standard Regimen vs. Capecitabine for Breast Cancer

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the journal The Oncologist, researchers have found that the continuous capecitabine regimen (Ccont) is not noninferior to the approved intermittent capecitabine regimen (Cint) for the treatment of patients with metastatic breast cancer.

The Cint regimen consists of capecitabine at a dose of 1,250mg/m2 twice daily for 2 weeks on and 1 week off versus the Ccont regimen that is capecitabine 800mg/m2 twice daily for each 21-day cycle.

 For the study, researchers randomly assigned 195 patients with HER2/neu-negative metastatic breast cancer to either Cint or Ccont in order to assess noninferiority of Cint to Ccont.

Results showed that at 1 year, progression-free survival was 27.3% for the Cint group compared with 25.3% for the Ccont group (Difference = -2.0%; 95% CI: -15.5 - 11.5). This value exceeded the 15% deemed noninferior. No differences regarding efficacy were identified between the two groups. In regard to safety, hand-and-foot syndrome was observed in 41.1% of those treated with Cint versus 42.3% in Ccont.

The findings suggest that Ccont is not noninferior to the standard Cint for the treatment of women with metastatic breast cancer. The researchers note that further research should be conducted to improve hand-and-foot syndrome.

Adding the PI3K inhibitor pictilisib (GDC-0941) to anastrozole (ANA) improves anti proliferative res
Capecitabine is not noninferior to approved intermittent capecitabine regimen for the treatment of metastatic breast cancer.
The authors tested a continuous regimen with a lower daily dose but a similar cumulative dose in an attempt to reduce the severity of adverse events (AEs) while maintaining efficacy. This study was unable to show noninferiority with the continuous capecitabine regimen (Ccont) compared with the approved intermittent regimen (Cint).

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs